Results 1 to 10 of about 8,080,314 (298)

Treatment resistant depression in women with peripartum depression [PDF]

BMC Pregnancy and Childbirth, 2019
Background Peripartum depression is a leading cause of disease burden for women and yet there is little evidence as to how often peripartum depression does not respond to treatment and becomes treatment resistant depression.
M. Soledad Cepeda, David M. Kern, Susan Nicholson   +2 more
doaj   +3 more sources

Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression

Pharmaceuticals, 2023
Treatment-resistant depression (TRD) is a term used to describe a particular type of major depressive disorder (MDD). There is no consensus about what defines TRD, with various studies describing between 1 and 4 failures of antidepressant therapies, with
Courtney M. Vecera, Alan C. Courtes, Gregory Jones, Jair C. Soares, Rodrigo Machado-Vieira   +4 more
doaj   +3 more sources

Socioeconomic barriers to psychotherapy engagement in treatment-resistant depression [PDF]

BJPsych Bulletin
Verônica de Oliveira Reis, Antonio E Nardi, Stephanie Zakhour   +2 more
doaj   +2 more sources

Potential efficacy of dopaminergic antidepressants in treatment resistant anergic-anhedonic depression results of the chronic anergic-anhedonic depression open trial – CADOT

Frontiers in Psychiatry, 2023
IntroductionAmong treatment-resistant depression (TRD), we identified anergic-anhedonic clinical presentations (TRAD) as putatively responsive to pro-dopaminergic strategies.
Ludovic Christophe Dormegny-Jeanjean, Ludovic Christophe Dormegny-Jeanjean, Ludovic Christophe Dormegny-Jeanjean, Clément de Billy, Clément de Billy, Clément de Billy, Olivier Mainberger, Olivier Mainberger, Olivier Mainberger, Sébastien Weibel, Sébastien Weibel, Sébastien Weibel, Benoit Schorr, Benoit Schorr, Benoit Schorr, Alexandre Obrecht, Alexandre Obrecht, Lionel Landré, Fabrice Berna, Fabrice Berna, Jean-Baptiste Causin, Jean-Baptiste Causin, Jean-Baptiste Causin, Frederic Blanc, Frederic Blanc, Vlad Danila, Vlad Danila, Mihaela Tomsa, Mihaela Tomsa, Geraldine Pfleger, Geraldine Pfleger, Camille Meyer, Camille Meyer, Camille Meyer, Ilia Humbert, Ilia Humbert, Ilia Humbert, Hervé Javelot, Hervé Javelot, Guillaume Meyer, Guillaume Meyer, Gilles Bertschy, Gilles Bertschy, Gilles Bertschy, Jack Rene Foucher, Jack Rene Foucher, Jack Rene Foucher, Jack Rene Foucher   +47 more
doaj   +1 more source

Ketamine in treatment-resistant depression

Industrial Psychiatry Journal
Sana Dhamija, Suprakash Chaudhury, Bhushan Chaudhari   +2 more
doaj   +5 more sources

Treatment-resistant depression reconsidered

SSM - Mental Health, 2022
The term treatment-resistant depression (TRD) has been the focus of hundreds of studies and clinical trials, though it is not a diagnosable mental health condition according to current clinical standards.
Hans S. Schroder, Elissa H. Patterson, Laura Hirshbein   +2 more
doaj   +1 more source

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression

European Psychiatry, 2022
Introduction The compassionate use of intranasal esketamine is approved in Spain for treatment-resistant depression (TRD). Objectives The objective of the study is to assess the clinical stability in the medium-term follow-up of patients with TRD after
D. Hernandez Huerta, A. De Santiago Diaz, C. Rodriguez Gomez-Carreño, M.A. Abril Garcia, F. Toledo Romero, A. Guerrero Morcillo, C.J. Martinez Pastor, M. Vega Piñero   +7 more
doaj   +1 more source

Clinical efficacy and tolerability of Esketamine: a case series

European Psychiatry, 2022
Introduction Esketamine is a novel antidepressant approved by the FDA in 2019 in the form of an intranasal spray, recommended for Treatment-Resistant Depression (TRD).
C. Passani, N. Ragone, C.M. Congedo, B. Barbini, R. Zanardi, M.C. Cavallini, C. Colombo   +6 more
doaj   +1 more source

Psilocybin's Emerging Role in Combating Depressive Disorder

Journal of Education, Health and Sport, 2023
        In this review paper, we delve into the potential applicability of psilocybin - a naturally synthesized psychedelic substance found within select species of fungi, as a prospective avenue for depression treatment.
Anna Jaremek, Joanna Kępa, Norbert Kandefer, Michał Wyszkowski, Aleksandra Grabarczyk, Anna Pawlak, Sylwia Grad, Małgorzata Gregorek, Paweł Gregorek   +8 more
doaj   +1 more source

Effects of psilocybin-assisted therapy on treatment-resistant depression

European Psychiatry, 2021
Introduction Major depressive disorder is a highly prevalent clinical condition, affecting more than 300 million individuals worldwide. About 1/3 of patients with MDD fail to achieve remission despite treatment with multiple antidepressants and are ...
A. Fraga, D. Esteves-Sousa, J. Facucho-Oliveira, M. Albuquerque, M. Costa, P. Espada Dos Santos, N. Moura, A. Moutinho   +7 more
doaj   +1 more source